Bizily Scott's Insider Trades & SAST Disclosures
Bizily Scott's most recent trade in 4D Molecular Therapeutics Inc was a trade of 78,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Bizily Scott.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 78,500 | 78,500 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 500 | 10,379 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 16 Sep 2024 | 500 | 6,781 | - | 16.3 | 8,165 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 Sep 2024 | 500 | 7,281 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 19 Aug 2024 | 500 | 7,281 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 19 Aug 2024 | 500 | 6,781 | - | 15 | 7,500 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 500 | 10,879 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.11 per share. | 16 Jul 2024 | 1,750 | 6,781 | - | 27.1 | 47,443 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 Jul 2024 | 1,250 | 8,531 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 1,250 | 32,502 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 Jul 2024 | 500 | 7,281 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 500 | 11,379 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 Jul 2024 | 1,996 | 6,781 | - | 25 | 49,900 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 11 Jul 2024 | 1,996 | 8,777 | - | 15.8 | 31,497 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 1,996 | 23,004 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 21.36 per share. | 01 Jul 2024 | 4,248 | 1,737 | - | 21.4 | 90,758 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 01 Jul 2024 | 2,916 | 5,985 | - | 8.0 | 23,445 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 2,916 | 33,752 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 01 Jul 2024 | 1,332 | 3,069 | - | 6.5 | 8,645 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 1,332 | 11,879 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.71 per share. | 17 Jun 2024 | 1,750 | 1,737 | - | 23.7 | 41,494 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2024 | 1,250 | 36,668 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 17 Jun 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 17 Jun 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2024 | 500 | 13,211 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.34 per share. | 16 May 2024 | 1,283 | 2,204 | - | 25.3 | 32,514 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 1,250 | 37,918 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 May 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 May 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 500 | 13,711 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.75 per share. | 16 May 2024 | 467 | 1,737 | - | 25.8 | 12,027 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.74 per share. | 16 Apr 2024 | 1,750 | 1,737 | - | 25.7 | 45,045 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 Apr 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 1,250 | 39,168 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 Apr 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 500 | 14,211 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 31.78 per share. | 01 Apr 2024 | 8,153 | 1,737 | - | 31.8 | 259,102 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 2,916 | 40,418 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 01 Apr 2024 | 2,916 | 5,985 | - | 8.0 | 23,445 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,996 | 21,008 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 01 Apr 2024 | 1,996 | 7,981 | - | 15.8 | 31,497 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,909 | 46,182 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.24 per share. | 01 Apr 2024 | 1,909 | 9,890 | - | 20.2 | 38,638 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 01 Apr 2024 | 1,332 | 3,069 | - | 6.5 | 8,645 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,332 | 14,711 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 27 Mar 2024 | 5,833 | 1,737 | - | 35.0 | 204,410 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2024 | 4,342 | 55,658 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.98 per share. | 27 Mar 2024 | 4,342 | 6,079 | - | 26.0 | 112,805 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2024 | 1,491 | 54,167 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.98 per share. | 27 Mar 2024 | 1,491 | 7,570 | - | 26.0 | 38,736 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 31.27 per share. | 18 Mar 2024 | 1,750 | 1,737 | - | 31.3 | 54,723 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 18 Mar 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2024 | 1,250 | 43,334 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2024 | 500 | 16,043 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 18 Mar 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.24 per share. | 27 Feb 2024 | 1,909 | 3,646 | - | 20.2 | 38,638 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 27 Feb 2024 | 1,909 | 1,737 | - | 30 | 57,270 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 1,909 | 48,091 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.67 per share. | 16 Feb 2024 | 1,750 | 1,737 | - | 27.7 | 48,423 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 Feb 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 1,250 | 44,584 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 500 | 16,543 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 Feb 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 2,916 | 45,834 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 08 Feb 2024 | 2,916 | 4,653 | - | 8.0 | 23,445 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 08 Feb 2024 | 2,916 | 1,737 | - | 27.5 | 80,190 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 08 Feb 2024 | 1,996 | 3,733 | - | 15.8 | 31,497 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,996 | 23,004 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 08 Feb 2024 | 1,996 | 1,737 | - | 27.5 | 54,890 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 08 Feb 2024 | 1,332 | 3,069 | - | 6.5 | 8,645 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 08 Feb 2024 | 1,332 | 1,737 | - | 27.5 | 36,630 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,332 | 17,043 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal and HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 08 Jun 2023 | 3,750 | 5,487 | - | 8.0 | 30,150 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 20.85 per share. | 08 Jun 2023 | 3,750 | 1,737 | - | 20.9 | 78,188 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 3,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 18.31 per share. | 01 Jun 2023 | 2,247 | 1,737 | - | 18.3 | 41,143 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 1,875 | 18,375 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 01 Jun 2023 | 1,875 | 3,984 | - | 6.5 | 12,169 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 21 Apr 2023 | 3,750 | 5,859 | - | 8.0 | 30,150 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 21 Apr 2023 | 3,750 | 2,109 | - | 20 | 75,000 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2023 | 3,750 | 52,500 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 19.30 per share. | 01 Mar 2023 | 2,248 | 2,109 | - | 19.3 | 43,386 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,875 | 20,250 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 01 Mar 2023 | 1,875 | 4,357 | - | 6.5 | 12,169 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 01 Dec 2022 | 3,750 | 6,607 | - | 8.0 | 30,150 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 3,750 | 56,250 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 22.93 per share. | 01 Dec 2022 | 2,450 | 3,157 | - | 22.9 | 56,180 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 01 Dec 2022 | 1,875 | 4,732 | - | 6.5 | 12,169 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 1,875 | 22,125 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 21.78 per share. | 01 Dec 2022 | 1,000 | 5,607 | - | 21.8 | 21,775 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 22.71 per share. | 01 Dec 2022 | 975 | 3,357 | - | 22.7 | 22,147 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 01 Dec 2022 | 400 | 2,957 | - | 23.3 | 9,300 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 21.52 per share. | 01 Dec 2022 | 400 | 4,332 | - | 21.5 | 8,606 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 24.35 per share. | 01 Dec 2022 | 375 | 2,482 | - | 24.3 | 9,131 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 23.44 per share. | 01 Dec 2022 | 200 | 2,957 | - | 23.4 | 4,688 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 24.49 per share. | 01 Dec 2022 | 100 | 2,857 | - | 24.5 | 2,449 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Sale of securities on an exchange or to another person at price $ 24.49 per share. | 01 Dec 2022 | 100 | 2,857 | - | 24.5 | 2,449 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal and HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2022 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges